NASDAQ:NURO NeuroMetrix (NURO) Stock Forecast, Price & News $0.64 0.00 (0.00%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$0.61▼$0.6550-Day Range$0.64▼$0.9852-Week Range$0.60▼$3.45Volume43,486 shsAverage Volume65,890 shsMarket Capitalization$5.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About NeuroMetrix (NASDAQ:NURO) StockNeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.Read More NURO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NURO Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comNeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.comAugust 30, 2023 | finance.yahoo.comNeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023September 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 28, 2023 | finance.yahoo.comIs NeuroMetrix (NURO) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapJuly 27, 2023 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Reports Q2 2023 Business HighlightsJuly 27, 2023 | finance.yahoo.comNeuroMetrix Reports Q2 2023 Business HighlightsJuly 20, 2023 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference CallJuly 11, 2023 | finance.yahoo.comNeuroMetrix Announces Sales Force Expansion for Quell FibromyalgiaSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJune 28, 2023 | finance.yahoo.comRecent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes PatientsJune 7, 2023 | finance.yahoo.comDiabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical StudyMay 31, 2023 | finance.yahoo.comQuell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)May 16, 2023 | bizjournals.comAutonomous delivery vehicle startup Nuro is cutting staff and production to focus on R&DMay 3, 2023 | finance.yahoo.comNeuroMetrix Reports Q1 2023 Financial ResultsApril 28, 2023 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference CallMarch 21, 2023 | finance.yahoo.comNeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual MeetingMarch 14, 2023 | thestreet.comWhy NeuroMetrix (NURO) Stock Is Soaring TodayFebruary 25, 2023 | finance.yahoo.comNeuroMetrix Full Year 2022 Earnings: US$0.62 loss per share (vs US$0.45 loss in FY 2021)February 23, 2023 | finance.yahoo.comNeuroMetrix Reports Q4 and Full Year 2022 Financial ResultsFebruary 16, 2023 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference CallFebruary 7, 2023 | thestreet.comNeuroMetrix (NURO) Stock Gains After Launching Diabetes Test in MexicoJanuary 23, 2023 | finance.yahoo.comNeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral NeuropathyDecember 11, 2022 | finance.yahoo.comNeuroMetrix, Inc. (NURO) Stock Historical Prices & Data - Yahoo FinanceNovember 8, 2022 | finance.yahoo.comNeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual MeetingNovember 3, 2022 | finance.yahoo.comNeuroMetrix Announces Strategic Launch of Quell FibromyalgiaOctober 20, 2022 | benzinga.comNeuroMetrix shares are trading lower after the company reported Q3 EPS and sales results were down year over year. - NeuroMetrix (NASDAQ:NURO) - BenzingaOctober 20, 2022 | globenewswire.comNeuroMetrix Reports Q3 2022 Financial Results - GlobeNewswireSee More Headlines Receive NURO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter. Email Address NURO Company Calendar Last Earnings7/27/2023Today9/26/2023Next Earnings (Estimated)10/19/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NURO CUSIPN/A CIK1289850 Webwww.neurometrix.com Phone(781) 890-9989Fax302-636-5454Employees27Year Founded1996Profitability EPS (Most Recent Fiscal Year)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,420,000.00 Net Margins-75.17% Pretax Margin-75.17% Return on Equity-24.38% Return on Assets-22.75% Debt Debt-to-Equity Ratio0.01 Current Ratio18.42 Quick Ratio17.11 Sales & Book Value Annual Sales$8.26 million Price / Sales0.64 Cash FlowN/A Price / Cash FlowN/A Book Value$3.01 per share Price / Book0.20Miscellaneous Outstanding Shares8,590,000Free Float7,941,000Market Cap$5.25 million OptionableNot Optionable Beta2.28 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Shai N. Gozani M.D. (Age 58)Ph.D., Founder, Chairman, CEO, Pres & Sec. Comp: $437.82kMr. Thomas T. Higgins (Age 71)Sr. VP, CFO & Treasurer Comp: $342.87kDr. Xuan Kong Ph.D.Chief Data ScientistMs. Susan M. Bell R.N.Sr. VP of Population Health & Value Based CareKey CompetitorsGlucoTrackNASDAQ:GCTKQuoin PharmaceuticalsNASDAQ:QNRXAethlon MedicalNASDAQ:AEMDFemasysNASDAQ:FEMYPolyPidNASDAQ:PYPDView All Competitors NURO Stock - Frequently Asked Questions How have NURO shares performed in 2023? NeuroMetrix's stock was trading at $1.49 on January 1st, 2023. Since then, NURO shares have decreased by 59.0% and is now trading at $0.6116. View the best growth stocks for 2023 here. Are investors shorting NeuroMetrix? NeuroMetrix saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 26,100 shares, an increase of 76.4% from the August 15th total of 14,800 shares. Based on an average daily volume of 79,100 shares, the days-to-cover ratio is presently 0.3 days. View NeuroMetrix's Short Interest. When is NeuroMetrix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 19th 2023. View our NURO earnings forecast. How were NeuroMetrix's earnings last quarter? NeuroMetrix, Inc. (NASDAQ:NURO) released its quarterly earnings results on Thursday, July, 27th. The medical device company reported ($0.19) EPS for the quarter. The medical device company earned $1.66 million during the quarter. NeuroMetrix had a negative net margin of 75.17% and a negative trailing twelve-month return on equity of 24.38%. When did NeuroMetrix's stock split? Shares of NeuroMetrix reverse split before market open on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What is Shai N. Gozani's approval rating as NeuroMetrix's CEO? 10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeuroMetrix own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), ReWalk Robotics (RWLK), Aurora Cannabis (ACB), Advanced Micro Devices (AMD) and Vaxart (VXRT). What is NeuroMetrix's stock symbol? NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO." How do I buy shares of NeuroMetrix? Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NeuroMetrix's stock price today? One share of NURO stock can currently be purchased for approximately $0.61. How much money does NeuroMetrix make? NeuroMetrix (NASDAQ:NURO) has a market capitalization of $5.25 million and generates $8.26 million in revenue each year. The medical device company earns $-4,420,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis. How can I contact NeuroMetrix? NeuroMetrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The official website for the company is www.neurometrix.com. The medical device company can be reached via phone at (781) 890-9989, via email at neurometrix.ir@neurometrix.com, or via fax at 302-636-5454. This page (NASDAQ:NURO) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroMetrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.